173 reports of this reaction
3.4% of all RUFINAMIDE reports
#4 most reported adverse reaction
SOMNOLENCE is the #4 most commonly reported adverse reaction for RUFINAMIDE, manufactured by Eisai Inc.. There are 173 FDA adverse event reports linking RUFINAMIDE to SOMNOLENCE. This represents approximately 3.4% of all 5,100 adverse event reports for this drug.
Patients taking RUFINAMIDE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among RUFINAMIDE users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for RUFINAMIDE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 173 FDA reports for RUFINAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 3.4% of all adverse event reports for RUFINAMIDE, making it a notable side effect.
If you experience somnolence while taking RUFINAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.